The story archive

Every discovery.
A little clearer.

Browse the collection, follow a topic, or find the story that sparked your curiosity.

Topic

500 published stories

385

Drug Development

AI Screens Thousands of Plant Chemicals for New Tuberculosis Drugs

Tuberculosis remains a massive global health challenge, especially as the bacteria responsible for it become increasingly resistant to existing drugs. To find new treatments, scientists are looking at phytochemicals, which are naturally occurring chemical compounds found in plants. Because testing these molecules one by one in a physical lab would take years, researchers recently used advanced artificial intelligence to speed up the discovery process. They trained a machine learning model on a massive database of over 425,000 compounds, teaching the computer to accurately predict what a successful drug against tuberculosis looks like. Once the computer learned the right chemical patterns, the team used it to screen a library of 4,707 plant-based chemicals. The algorithm narrowed this list down to 778 high-confidence candidates. To understand how these candidates might function, the researchers used a computer simulation called molecular docking. This technique tests how well a molecule physically fits into essential parts of the bacteria, much like a key sliding into a lock. The simulation revealed that 486 of these plant compounds have favorable properties for binding to the bacteria, with some capable of attacking multiple targets at once. The team also used a special analytical tool to look inside the algorithmic black box, allowing them to isolate the exact molecular features that drove the predictions of the artificial intelligence. However, the researchers emphasize a critical limitation. This study is completely computational and represents only the very first step in early-stage drug discovery. These findings will require rigorous real-world testing in physical lab experiments and animal models to confirm that the compounds are actually safe and effective.

PubMed · 2 min read

386

Oncology

Smart Shunt Valves Make Brain Cancer Treatment Safer for Kids

Children with severe brain tumors often need chemotherapy delivered directly into their cerebrospinal fluid. However, many of these young patients also suffer from fluid buildup in the brain, a condition called hydrocephalus. To treat this fluid buildup, doctors implant tubes called shunts to constantly drain the excess liquid. The problem is that these constant drainage systems can accidentally wash away the chemotherapy drugs before they have a chance to work, leaving the medication levels too low to effectively fight the cancer. To solve this challenge, researchers evaluated the use of programmable shunt valves. These smart devices act as a delivery system with a virtual off switch. By temporarily stopping the fluid drainage, doctors can ensure the chemotherapy stays in the cerebrospinal fluid at the right concentration. The researchers reviewed the cases of 18 children who received their cancer medication through these programmable valves. The technique proved to be highly secure. The study reported a strong safety profile with no infections, fluid leaks, or delayed side effects related to the treatments. While this was a retrospective study with a small sample size that requires further validation, the early results are highly promising for pediatric cancer care.

PubMed · 1 min read

387

Drug Development

Alzheimer's drug demand lags as estrogen patches face supply shortages

Recently approved medications for Alzheimer's disease, specifically Leqembi and Kisunla, are not reaching as many patients as federal officials originally expected. Medicare adoption for these treatments is significantly lower than initial projections. This sluggish demand stems from several practical and medical hurdles that make the drugs challenging to use. The slow rollout is tied to the strict requirements for administering these therapies. Patients must receive the medication through an intravenous drip and undergo frequent medical imaging. On top of these logistical hurdles, the drugs are only suitable for a limited group of eligible patients. Finally, the medications carry the risk of severe side effects, including brain bleeding, which can make both doctors and patients cautious. In a separate medical trend, estrogen patches are becoming increasingly difficult to find. Hormone replacement therapy has seen a massive boom in popularity since the Food and Drug Administration removed a severe safety alert, known as a black box warning, from the treatments late last year. While the American Society of Health-System Pharmacists reports that 14 different brands or dosages of estrogen patches are currently in short supply, it is worth noting that the FDA has not yet officially added them to its own drug shortage list.

STAT News · 2 min read

388

Gene Therapy

Gene and RNA Therapies Rebound with a Surge in Startups and New Targets

The field of genetic medicine is experiencing a significant resurgence. According to a recent industry report, worldwide approvals have now reached 42 gene therapies, 38 RNA therapies, and 76 cell therapies that are not genetically modified. This clinical success is mirrored by a rebounding business landscape. In the first quarter of the year, 26 new startup companies were formed in this sector, a number that sits well above the historical average of five to twenty. Alongside this growth, researchers are shifting their focus toward a wider variety of diseases. While these advanced treatments have historically been associated with fighting cancer, over 60 percent of current gene therapy clinical trials are now targeting non-cancer conditions. In the realm of RNA medicine, a fascinating split is occurring. Therapies based on RNA interference (a technique known as RNAi that helps silence faulty genes) are seeing strong pipeline growth. On the other hand, therapies using messenger RNA (mRNA, which gives cells temporary instructions to make proteins) are actually experiencing a decline quarter over quarter. Despite these promising signals, it is important to note that most of this research is still in its infancy. While the overall pipeline of potential new medicines is massive, the vast majority of these assets remain in the earliest stages of human testing. Currently, there are 669 gene therapy trials in Phase I or Phase II (the initial stages to check safety and basic effectiveness) compared to only 41 trials that have made it to the final Phase III stage.

GEN · 2 min read

389

Oncology

Inhibrx drug combo doubles patient response in early trial

Researchers at Inhibrx Biosciences are exploring a new combination of treatments that could make a significant difference for patients. In a recent clinical trial, the company combined an experimental drug known as an OX40 agonist with Keytruda, an established therapy. An agonist is simply a substance that stimulates a specific biological response in the body, often used to help the immune system gear up for a fight. The results of combining these two drugs were highly positive. According to the data, adding the Inhibrx medication to Keytruda doubled the patient response rate. Because of these encouraging clinical outcomes, Inhibrx is now moving forward to advance the research program to its next steps. However, it is important to keep early expectations in check. These findings are based on a preliminary look at data from a mid-stage clinical trial. The final effectiveness of this drug combination has not yet been proven, and researchers will need to firmly establish its true clinical value in completed, late-stage clinical trials.

Fierce Biotech · 1 min read

390

Digital Health

Making AI a Safer Tool for Brain Cancer Radiotherapy

When doctors treat brain cancer with radiation, they must carefully map out the surrounding healthy organs to avoid damaging them. Artificial intelligence tools are increasingly used to automate this process, examining magnetic resonance imaging, or MRI, scans to draw boundaries around critical structures like the brainstem. While these standard AI models are highly accurate at mapping large areas, they have a major flaw. They are often overly confident in their predictions, even when looking at blurry or hard-to-read parts of a scan. To solve this, researchers tested a modified AI system called a deep residual encoder, or ResEncM. They compared this new model against a standard AI framework using MRI scans from 70 patients with brain cancer. The goal was to see if the modified AI could accurately identify healthy brain structures while also recognizing when it was uncertain about a specific boundary. The results showed a fascinating trade-off. Both AI models proved highly accurate at outlining large areas like the brainstem and the hippocampi, which are crucial for memory. The modified model struggled slightly more than the standard AI when drawing the exact boundaries of smaller, complex structures like the pituitary gland and the optic nerves. However, it was significantly better at knowing its own limits. By reliably flagging the exact areas where it was unsure, the new model provided a much safer and more realistic assessment of the scan.

PubMed · 2 min read

391

Drug Development

How Japan Speeds Up Antimicrobial Approvals Using Global Data

When a pharmaceutical company wants to sell a new medicine in a different country, regulators usually demand local clinical trials to prove it works safely for their specific population. However, a new analysis shows that Japan has been taking a more global approach to approving antimicrobial medicines like antibiotics and antivirals. Researchers found that foreign clinical trial data played a key role in evaluating the effectiveness of more than 60 percent of approved antimicrobial drugs in the country. In fact, Japanese regulators approved 40 of these medicines without requiring extra domestic bridging studies, which are smaller local trials meant to confirm foreign results. Instead of forcing companies to run redundant tests, regulators looked closely at pharmacokinetic data, which measures how the human body absorbs and processes a drug. They combined this with pharmacodynamic data, which looks at how effectively the drug fights a specific infection, along with outside factors like the local healthcare environment. While this streamlined process is highly successful, it does not mean regulators ignore local biological differences. In one notable case, variations in how Japanese patients processed a medication required regulators to approve a completely different dosage than what was used overseas. The researchers also caution that this retrospective study only looked at antimicrobials within the unique regulatory framework of Japan, so this approach might not necessarily apply to other types of medical treatments or different global regions.

PubMed · 2 min read

392

Gene Therapy

Novel Gene Therapy Shows Early Promise for Delaying Huntington's Disease

Latus Bio, a biotechnology company, is developing a new gene therapy for central nervous system disorders, starting with Huntington's disease. Their lead candidate, called LTS-201, relies on a newly designed delivery vehicle. In gene therapy, scientists often use harmless, modified viruses known as adeno-associated viruses, or AAVs, to carry treatments directly into cells. The researchers identified a specific outer shell of the virus, called a capsid, that excels at this task. Named AAV-DB-3, this new capsid successfully delivered genetic material deep into the brain cells of monkeys using just a single, low-dose infusion per brain hemisphere. Once inside the brain, the therapy works by targeting a specific DNA repair protein called MSH3. In Huntington's disease, certain repeating DNA sequences abnormally expand over time and cause cellular damage. To stop this, the therapy uses an artificial microRNA, which is a tiny molecule specially designed to dial down the production of the MSH3 protein. By lowering the levels of this protein, the researchers aim to reduce these harmful DNA expansions and delay the onset of the disease. The early results are highly encouraging but still in the laboratory testing phase. In animal studies, the treatment reduced MSH3 levels by 50 percent in specialized mice and by 48 to 94 percent in non-human primates. However, it is important to note that this research is strictly in its preclinical stages and has not yet been tested in humans. The company plans to submit an Investigational New Drug application, a necessary step before human clinical trials can begin, in the second half of 2026.

GEN · 2 min read

393

Digital Health

Supreme Court Preserves Telehealth Access to Mifepristone for Now

The Supreme Court has decided that mifepristone, a key medication used in medical abortions, can still be prescribed through telehealth and delivered by mail for the time being. This decision reverses a recent ruling by the 5th Circuit Court of Appeals, which had attempted to temporarily block doctors from prescribing the medication remotely. The legal dispute centers on safety protocols known as Risk Evaluation and Mitigation Strategies. Originally, these rules required patients to obtain mifepristone in person, but the Food and Drug Administration lifted those specific restrictions in 2021 to allow remote prescribing. The state of Louisiana is currently challenging this change in court, arguing that allowing doctors to prescribe the drug via telehealth directly undermines the state's strict abortion ban. It is important to note that the current Supreme Court decision is only a temporary measure. The broader case will continue to move its way through the justice system, meaning the ultimate legality of telehealth distribution for mifepristone remains highly uncertain.

STAT News · 1 min read

394

Oncology

Cancer Care Program Yields $328 Million in Lasting Savings

When the federal government launched the Oncology Care Model, the goal was to improve the quality of care for Medicare patients receiving chemotherapy while keeping a lid on spending. The voluntary program offered clinics financial incentives to hit specific quality and cost targets. Now, researchers have discovered that the cost-saving habits clinics developed during the program stuck around well after it officially ended. For a full 18 months following the conclusion of the model, participating practices successfully sustained their payment reductions. During this post-program period, clinics reduced the total cost of a patient care episode by an average of $955. The bulk of these savings was driven by a $559 reduction in Medicare Part B payments, which typically cover outpatient medical services. Interestingly, the researchers found that these specific savings came mostly from spending less on non-chemotherapy drugs. The study does note some limitations based on how it looked back at past Medicare fee-for-service claims. Because the program was voluntary, the results might reflect a natural selection bias, meaning the clinics that opted in may have already been better equipped to manage costs. However, the data clearly showed that the most dramatic savings came from practices that adopted "two-sided risk." In this setup, clinics could earn bonuses for saving money but also faced financial penalties if they exceeded their budgets. These practices successfully lowered costs across multiple parts of the Medicare system.

PubMed · 2 min read

395

General Biotech

Supreme Court Temporarily Protects Mail Access to Abortion Pills

The U.S. Supreme Court has stepped in to temporarily protect how patients receive the abortion medication mifepristone. In a recent emergency order, the justices paused a lower court ruling that would have blocked patients from getting the drug by mail or through telehealth appointments. For now, the medication remains accessible under current rules. The dispute centers on a 2021 policy from the Food and Drug Administration that made it easier to prescribe the pill without a physical doctor visit. A federal appeals court recently tried to overturn this FDA policy, declaring that patients must see a medical provider in person before receiving the medication. Drug manufacturers Danco and GenBioPro quickly pushed back. They warned that abruptly changing the rules would create immediate regulatory chaos and disrupt time-sensitive medical care. However, this Supreme Court decision is not a final legal resolution. The justices only issued an emergency stay, which acts as a temporary pause button on the restrictions while the underlying legal battle continues to work its way through the judicial system.

BioPharma Dive · 1 min read

396

Gene Therapy

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

For decades, doctors have used harmless viruses known as adeno-associated viruses, or AAVs, as biological delivery trucks to treat genetic diseases. These viruses are engineered to carry healthy genes directly into a patient's cells. But a newly published study reveals an unexpected complication. Researchers recently linked a specific brain tumor in a five-year-old boy to an AAV9 gene therapy he received as an infant to treat an inherited disorder called MPS1 deficiency. When the boy was five, doctors discovered a rare neuroepithelial tumor in his brain. By sequencing the genetic material of the mass, scientists found that the gene therapy payload had accidentally woven itself into the boy's own genome. Specifically, the viral delivery cassette fused with a human gene called PLAG1, which is known to drive tumor growth. Curiously, the tumor also contained a stray fragment of a different human chromosome, which researchers suspect was a manufacturing contaminant from when the viral vector was created. Thankfully, the story has a positive outcome so far. Surgeons successfully removed the tumor. Eight months after the operation, the patient shows no signs of the tumor returning and is actually demonstrating advanced cognitive development.

GEN · 1 min read